Chromosome changes in a patient achieving complete remission in the acute phase of chronic myelogenous leukemia
โ Scribed by Ronald Stern; Julie Sorenson; Doris H. Wurster-Hill; Gibbons G. Cornwell III; O. Ross McIntyre
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- English
- Weight
- 449 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## BACKGROUND. Interleukin-2 (IL-2) has immunomodulatory effects, including stimulating the activity of cytotoxic T cells and natural killer cells, and inducing the generation of lymphokine-activated killer cells. The authors investigated whether IL-2 may improve the duration of complete remission
## Background: Patients with chronic myelogenous leukemia (cml) occasionally experience persistent thrombocythemia despite having adequate white blood cell (wbc) counts. trimethylenethiophosphoramide (thiotepa) is an alkylating agent that significantly inhibits platelet production. ## Methods: Th
To the Editor: Semenzato et al. proposed new criteria for large granular lymphocyte (LGL) leukemia because patients with low levels of GL were similar to those with levels greater than 2,000 GL/l [1]. LGL leukemia is a GL proliferative disease often accompanied by pure red cell aplasia (PRCA). T-cel